Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dalpiciclib |
Synonyms | |
Therapy Description |
Dalpiciclib (SHR6390) inhibits CDK4/6, which may lead to cell cycle arrest and tumor growth inhibition (PMID: 30724426). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dalpiciclib | SHR 6390|SHR-6390|SHR6390 | CDK4/6 Inhibitor 14 | Dalpiciclib (SHR6390) inhibits CDK4/6, which may lead to cell cycle arrest and tumor growth inhibition (PMID: 30724426). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 positive | colon cancer | sensitive | Dalpiciclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Dalpiciclib (SHR6390) inhibited CDK4/6-RB pathway activation, leading to growth inhibition in an RB1-positive colon cancer cell line in culture, and tumor regression in a cell line xenograft model (PMID: 30724426). | 30724426 |
RB1 dec exp | Advanced Solid Tumor | no benefit | Dalpiciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Dalpiciclib (SHR6390) demonstrated limited cytotoxic activity against tumor cell lines with low Rb1 expression in culture (PMID: 30724426). | 30724426 |
RB1 negative | breast cancer | no benefit | Dalpiciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Dalpiciclib (SHR6390) demonstrated little cytotoxic activity against a RB1-negative breast cancer cell line in culture (PMID: 30724426). | 30724426 |
RB1 positive | Advanced Solid Tumor | sensitive | Dalpiciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Dalpiciclib (SHR6390) inhibited CDK4/6-RB pathway signaling, leading to cell cycle arrest and inhibition of proliferation in a panel of RB1-positive tumor cell lines in culture, and tumor growth inhibition in cell line xenograft models (PMID: 30724426). | 30724426 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|